Physician profile
Christopher A Tomassian
NPI 1871097550
$208,157.24
in general payments reported to CMS, 2019-2025
19 companies · $42K in 2025
The $42K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $201 · 2021: $344 · 2022: $17K · 2023: $104K · 2024: $44K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $186K · Food and Beverage: $4,336 · Travel and Lodging: $201 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $186,400.00 |
| Food and Beverage | $4,336.21 |
| Travel and Lodging | $201.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $203,402.26 | 2022-2025 | Nemluvio |
| Genzyme Corporation | $1,184.27 | 2021-2025 | |
| Abbvie INC. | $928.67 | 2021-2025 | Skyrizi |
| Regeneron Healthcare Solutions, INC. | $814.21 | 2023-2025 | Dupixent |
| Incyte Corporation | $319.32 | 2023-2025 | Opzelura |
| Lilly USA, LLC | $243.54 | 2021-2022 | |
| Revance Therapeutics, INC. | $241.60 | 2025 | Daxxify |
| Amgen INC. | $220.70 | 2020-2025 | Otezla |
| Janssen Biotech, INC. | $195.76 | 2025 | Tremfya |
| Stryker Corporation | $161.11 | 2022 | |
| Merz North America, INC. | $155.10 | 2022-2023 | Xeomin |
| Ucb, INC. | $76.21 | 2025 | Bimzelx |
| Pfizer INC. | $46.30 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $42.69 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $42.65 | 2025 | Zoryve |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $29.24 | 2022 | |
| Medline Industries LP | $24.24 | 2025 | |
| Leo Pharma INC. | $18.17 | 2024 | Adbry |
| Helsinn Therapeutics (U.S.), INC. | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Tomassian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.